Stevenage, UK, 30 March 2023 – NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of its scientific advisory board (SAB), to support and steer its R&D programmes to develop novel small molecule therapies for the treatment of neurodegenerative disorders. The four founding members of NRG’s International SAB […]
Stevenage, UK, 22 February 2023 – NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a second $500,000 grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to support its lead drug discovery programme and the development of a novel treatment for Parkinson’s. […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2023-02-22 08:00:322026-07-31 12:29:11NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme
Gilles Ouvry Ph.D, appointed to newly created position of VP of Chemistry, based in Stevenage, UK Joins from Evotec, UK and brings 20 years of international medicinal chemistry experience including at Galderma, AstraZeneca and SCYNEXIS Will be responsible for developing NRG’s pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2023-02-09 08:00:212026-07-31 12:31:59NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
£16 million Series A led by Omega Funds, to advance disease-modifying oral medicines for debilitating chronic neurodegenerative disorders through IND-enabling studies Developing a pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore, which act through a novel mechanism of action, as treatments for Parkinson’s and Amyotrophic Lateral Sclerosis (ALS) Professor […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-09 08:00:152026-07-31 12:32:48NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinson’s and ALS
NRG Therapeutics Announces International Scientific Advisory Board
Stevenage, UK, 30 March 2023 – NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of its scientific advisory board (SAB), to support and steer its R&D programmes to develop novel small molecule therapies for the treatment of neurodegenerative disorders. The four founding members of NRG’s International SAB […]
NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme
Stevenage, UK, 22 February 2023 – NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a second $500,000 grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to support its lead drug discovery programme and the development of a novel treatment for Parkinson’s. […]
NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
Gilles Ouvry Ph.D, appointed to newly created position of VP of Chemistry, based in Stevenage, UK Joins from Evotec, UK and brings 20 years of international medicinal chemistry experience including at Galderma, AstraZeneca and SCYNEXIS Will be responsible for developing NRG’s pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore […]
NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinson’s and ALS
£16 million Series A led by Omega Funds, to advance disease-modifying oral medicines for debilitating chronic neurodegenerative disorders through IND-enabling studies Developing a pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore, which act through a novel mechanism of action, as treatments for Parkinson’s and Amyotrophic Lateral Sclerosis (ALS) Professor […]